Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: <i>in vitro</i> characterization, stability, <i>in vitro</i> cytotoxicity, and antiviral activity using real time cell analysis-Reference-Cited by-同舟云学术

Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

Published:2022-09-05 Issue:1 Volume:29 Page:2846-2854
ISSN:1071-7544
Container-title:Drug Delivery
language:en
Short-container-title:Drug Delivery

Author:

Yildiz Pekoz Ayca¹,Akbal Dagistan Ozlem¹,Fael Hanan¹,Culha Meltem¹,Erturk Aybige¹²,Basarir Nur Sena¹,Sahin Gokben³,Serhatli Muge⁴,Cakirca Gamze⁴⁵,Tekin Saban⁴⁶,Sen Leyla Semiha⁷,Sevim Mustafa⁷,Mulazimoglu Durmusoglu Lutfiye⁸,Yegen Berrak C.⁷

Affiliation:

1. Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul University, Istanbul, Türkiye

2. Faculty of Pharmacy, Department of Pharmaceutical Technology, Istinye University, Istanbul, Türkiye

3. Faculty of Pharmacy, Department of Pharmaceutical Technology, Trakya University, Istanbul, Türkiye

4. Medical Biotechnology (Marmara Research Center (MRC)), TUBITAK Marmara Research Center-MRC, Life Sciences, Kocaeli, Türkiye

5. Molecular Biology and Genetics, Institute of Natural and Applied Sciences, Gebze Technical University, Kocaeli, Türkiye

6. Hamidiye Faculty of Medicine, Department of Basic Medical Sciences, Medical Biology, University of Health Sciences, Istanbul, Türkiye

7. School of Medicine, Basic Medical Sciences, Department of Physiology, Marmara University, Istanbul, Türkiye

8. School of Medicine, Department of Infectious Diseases, Marmara University, Istanbul, Türkiye.

Publisher

Informa UK Limited

Subject

Pharmaceutical Science,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/10717544.2022.2118398

Reference44 articles.

1. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis

2. Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study

3. Transmission of coronavirus by nebulizer: a serious, underappreciated risk

4. The proximal origin of SARS-CoV-2

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action;Heliyon;2024-08

2. A novel multi-drugs ciprofloxacin-curcumin-N-acetylcysteine co-delivery system based on hybrid nanocrystals for dry powder inhalations;Next Nanotechnology;2024

3. Inhalation of vaccines and antiviral drugs to fight respiratory virus infections: reasons to prioritize the pulmonary route of administration;mBio;2023-10-31

4. A solvent-free HPLC method for the simultaneous determination of Favipiravir and its hydrolytic degradation product;Scientific Reports;2023-10-28

5. Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization;International Journal of Pharmaceutics;2023-10